SCHEMBL403023

SCHEMBL403023

N#Cc1ccc(Br)c(C(F)(F)F)c1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 1/20 0.53
KIF11 P52732 2/20 0.47
PTPN1 P18031 2/20 0.44
PTPN2 P17706 1/20 0.44
P4HB P07237 2/20 0.41
AR P10275 4/20 0.40
NOTUM Q6P988 1/20 0.39
MRGPRX4 Q96LA9 1/20 0.38
SLC22A12 Q96S37 3/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
TTR P02766 1/20 0.38
ALB P02768 1/20 0.38
MAPT P10636 2/20 0.37
LMNA P02545 1/20 0.37
XBP1 P17861 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
TMPRSS4 Q9NRS4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31026088 1.00 TRPV4 (0.53) TRPV4KIF11PTPN1PTPN2P4HB
SCHEMBL1824261 0.84 KIF11 (0.51) TRPV4KIF11PTPN1PTPN2AR
SCHEMBL7569957 0.81 TRPV4 (0.58) TRPV4KIF11P4HBARMRGPRX4
SCHEMBL12203361 0.80 CYP1A2 (0.44) TRPV4KIF11PTPN1PTPN2MEN1
SCHEMBL9367883 0.80 NOTUM (0.39) TRPV4PTPN1NOTUMMEN1KMT2A
SCHEMBL5546385 0.80 MAPT (0.41) TRPV4P4HBNOTUMMEN1KMT2A
SCHEMBL16955243 0.80 NOTUM (0.39) TRPV4KIF11NOTUMMEN1KMT2A
SCHEMBL7604551 0.79 TRPV4 (0.56) TRPV4KIF11P4HBARMRGPRX4
SCHEMBL10502974 0.78 TRPV4 (0.54) TRPV4KIF11P4HBARMRGPRX4
SCHEMBL185191 0.78 KIF11 (0.58) TRPV4KIF11P4HBARMRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115784839-B Preparation method of 4-cyclohexyl-3- (trifluoromethyl) benzyl alcohol 浙江工业大学 2024-06-21 CN claimed
CN-115784839-A Preparation method of 4-cyclohexyl-3- (trifluoromethyl) benzyl alcohol 浙江工业大学 2023-03-14 CN claimed
US-20260138974-A1 POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS LEUKOS BIOTECH S L (ES) 2026-05-21 US disclosed
US-12540133-B2 Potent and selective compounds as serotonin 1B receptor modulators LEUKOS BIOTECH, S.L. (ES) 2026-02-03 US disclosed
US-12465653-B2 Thienoazepine immunoconjugates, and uses thereof BOLT BIOTHERAPEUTICS, INC. (US) 2025-11-11 US disclosed
EP-4608553-A1 HETEROGENEOUS CATALYSTS DOW GLOBAL TECHNOLOGIES LLC (US) 2025-09-03 EP disclosed
CN-120152789-A Heterogeneous catalyst 陶氏环球技术有限责任公司 2025-06-13 CN disclosed
EP-4048315-B1 THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF BOLT BIOTHERAPEUTICS INC (US) 2025-03-12 EP disclosed
EP-3873900-B1 IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES GILEAD SCIENCES INC (US) 2025-01-08 EP disclosed
EP-4445901-A2 NEW POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS Leukos Biotech, S.L. (ES) 2024-10-16 EP disclosed
CN-112969700-B Imidazopyridine derivatives as alpha 4 beta 7 integrin inhibitors 吉利德科学公司 2024-08-20 CN disclosed
EP-1343791-A2 SUBSTITUTED TETRACYCLIC PYRIDOINDOLES AS SEROTONIN AGONISTS AND ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-09-17 EP disclosed
US-20020173503-A1 Substituted pyridoindoles as serotonin agonists and antagonists BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-11-21 US disclosed
CN-1370176-A Subsstituted heterocycle fused gamma-carbolines BRISTOL MYERS SQUIBB CO (US) 2002-09-18 CN disclosed
WO-2002059129-A2 SUBSTITUTED TETRACYCLIC PYRIDOINDOLES AS SEROTONIN AGONISTS AND ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2002-08-01 WO disclosed
EP-1192165-A2 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES Bristol-Myers Squibb Pharma Company (US) 2002-04-03 EP disclosed
WO-2000077010-A2 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES DU PONT PHARMACEUTICALS COMPANY (US) 2000-12-21 WO disclosed
US-5866610-A Substituted benzoylguanidines, process for their preparation, their use as a pharmaceutical as inhibitors of the cellular NA+/H+ exchange or as a diagnostic, and pharmaceutical containing them HOECHST AKTIENGESELLSCHAFT (DE) 1999-02-02 US disclosed
EP-0612723-B1 Substituted benzoylguanidines, process for their preparation, their use as medicament, as inhibitor of the cellular Na+/H+ exchange or as diagnostic agent and medicament containing them HOECHST AG (DE) 1997-08-27 EP disclosed
EP-0612723-A1 Substituted benzoylguanidines, process for their preparation, their use as medicament, as inhibitor of the cellular Na+/H+ exchange or as diagnostic agent and medicament containing them HOECHST AKTIENGESELLSCHAFT (DE) 1994-08-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020173503-A1 Substituted pyridoindoles as serotonin agonists and antagonists HTR1A, HTR1B, HTR7 TRPV4 576/4885KIF11 2835/4885PTPN1 688/4885
US-20260138974-A1 POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS HTR3B, HTR1B, HTR1A TRPV4 1307/4885KIF11 4801/4885PTPN1 1583/4885
US-12540133-B2 Potent and selective compounds as serotonin 1B receptor modulators HTR3B, HTR1A, HTR1B TRPV4 960/4885KIF11 4623/4885PTPN1 1594/4885
US-12465653-B2 Thienoazepine immunoconjugates, and uses thereof ICOS, CYP3A5, TPH1 TRPV4 1621/4885KIF11 1854/4885PTPN1 3525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.